Functional Neuromodulation Ltd., in partnership with Boston Scientific, is investigating the use of deep brain stimulation of the fornix (DBS-f) to drive neural activity and modulate the brain’s memory circuit. The company completed a Phase II multi-center clinical trial of DBS-f in 42 patients with mild probable Alzheimer’s in 2016. Functional Neuromodulation is dedicated to advancing the application of deep brain stimulation (DBS) therapies to help improve the lives of people with mild Alzheimer’s disease. Investors include Boston Scientific, Genesys Capital Partners, and MS Pace. CAUTION — Investigational device. Limited by Federal law to investigational use